ERBB2 and breast carcinoma: Accordingly, in all four subtypes as well as in the ‘all’ breast cancer category expression of EM_HMLER was also associated with poor relapse-free survival that was significant for all subtypes except for the rarely metastasizing luminal A and the HER2 subgroup.